Search company, investor...
Arena Pharmaceuticals company logo

Arena Pharmaceuticals

Founded Year



Acq - P2P | Acquired

Total Raised




About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory diseases, and metabolic diseases. Arena's most advanced drug candidate is lorcaserin. Arena's pipeline of compounds targets G protein-coupled receptors. On December 13th, 2021, Arena Pharmaceuticals was acquired by Pfizer.7B.

Headquarters Location

6166 Nancy Ridge Drive

San Diego, California, 92121,

United States


Missing: Arena Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Arena Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Arena Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Arena Pharmaceuticals is included in 2 Expert Collections, including Cannabis.



3,834 items

These companies participate in - or service businesses that participate in - the legal cannabis industry. Our definition of cannabis includes both marijuana and hemp (and all derivatives). The collection includes both "plant-touching" and "non-plant-touching" businesses.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Arena Pharmaceuticals Patents

Arena Pharmaceuticals has filed 180 patents.

The 3 most popular patent topics include:

  • Autoimmune diseases
  • Rare diseases
  • Designer drugs
patents chart

Application Date

Grant Date


Related Topics




Heart diseases, Cardiology, Cardiovascular physiology, Cardiomyopathy, Organ failure


Application Date


Grant Date



Related Topics

Heart diseases, Cardiology, Cardiovascular physiology, Cardiomyopathy, Organ failure



Latest Arena Pharmaceuticals News

North America Legal Cannabis Market Report 2022: Featuring 22nd Century, Medical Marijuana Inc, Arena Pharmaceuticals & More -

Jan 20, 2023

The North America legal cannabis market size reached US$ 20.5 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 111.9 Billion by 2027, exhibiting a CAGR of 32.69% during 2021-2027. In the United States, marijuana has been legalized in 30 states for medicinal use and in 9 states for both therapeutic as well as recreational purposes. In Canada, medicinal usage of the drug has been legalized since 2001; however, its recreational use has been authorized through a bill passed in June 2018. This modification in the regulatory landscape has led to an increase in the usage of medical cannabis for treating several diseases associated with changing lifestyles such as chronic pain, depression, post-traumatic stress disorder, social anxiety, cancer, multiple sclerosis and epilepsy. Also, with the implementation of these stringent regulations, suppliers have to comply with proper safety control measures and provide consumers with high-quality products, which further acts in favor of the growth of the market. The use of industrial hemp, a product derived from cannabis, has also expanded to a great variety of products, including health foods, organic body care, clothing, construction materials, biofuels and plastic composites. Moreover, increasing research and development (R&D) activities in the medical applications of cannabis are expected to create positive opportunities for both the existing players and new entrants in the upcoming years. Key Market Segmentation: The publisher provides an analysis of the key trends in each sub-segment of the North America legal cannabis market report, along with forecasts at the regional and country level from 2022-2027. Our report has categorized the market based on products derived and distribution channel. Breakup by Products Derived: Industrial Hemp Marijuana currently represents the leading segment. It is a greenish-grey mixture of the dried flowers of Cannabis sativa. The applications of marijuana are further divided on the basis of medical and recreational uses. Its therapeutic applications include the treatment of various diseases such as migraine, cancer, arthritis and others. Breakup by Distribution Channel:

Arena Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Arena Pharmaceuticals founded?

    Arena Pharmaceuticals was founded in 1997.

  • Where is Arena Pharmaceuticals's headquarters?

    Arena Pharmaceuticals's headquarters is located at 6166 Nancy Ridge Drive, San Diego.

  • What is Arena Pharmaceuticals's latest funding round?

    Arena Pharmaceuticals's latest funding round is Acq - P2P.

  • How much did Arena Pharmaceuticals raise?

    Arena Pharmaceuticals raised a total of $37.83M.

  • Who are the investors of Arena Pharmaceuticals?

    Investors of Arena Pharmaceuticals include Pfizer, Deerfield Management, HBM Healthcare Investments, HBM Partners, MPM Capital and 6 more.

  • Who are Arena Pharmaceuticals's competitors?

    Competitors of Arena Pharmaceuticals include Humanetics, Evotec SE, Integral Molecular, Hydra Biosciences, Diffusion Pharmaceuticals, aTyr Pharma, Pulmatrix, CymaBay Therapeutics, iPierian, Trius Therapeutics and 27 more.

Compare Arena Pharmaceuticals to Competitors


Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.


The company is engaged in developing and commercializing drugs for the hospital-based treatment of central nervous system (CNS) disorders and thrombotic/cardiovascular diseases, indications for which there is a substantial unmet medical need.

Neuraltus Pharmaceuticals

Neuraltus Pharmaceuticals is a privately-held biopharmaceutical company dedicated to developing and commercializing innovative therapeutics that address critical unmet needs for patients and physicians in the treatment of neurodegenerative diseases. The Company is collaborating with global ALS specialists and seeking input from patient advocacy organizations to help inform the clinical development path and better understand the needs of people affected by the disease.

Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

Actinobac Biomed

Actinobac Biomed is a biopharmaceutical company developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases, and HIV. Its drug candidates are based upon Leukothera (LtxA), a natural protein that targets and eliminates white blood cells (WBCs) involved in the mechanism of many diseases. Products based upon Leukothera are being developed by Actinobac for the treatment of leukemia/lymphoma, dry eye, and psoriasis.

Y's Therapeutics

Y's Therapeutics focuses on developing monoclonal antibody therapies and other molecular-targeted biological drugs for the treatment of inflammation-mediated diseases, cancer, and other unmet medical needs. The company also have small molecule compounds in the company's R&D pipeline to diversify the company's portfolio.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.